Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IMU-935

Other · developed by Immunic

Phase 1 Most advanced trial (none active)
IMUX Developer
1 Registered trials

What is IMU-935?

IMU-935 is an investigational drug studied in Metastatic Castration Resistant Prostate Cancer.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
Immunic AG (IMUX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05124795 Phase 1 Metastatic Castration Resistant Prostate Cancer Terminated IMUX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration Resistant Prostate Cancer

More from Immunic

Follow IMUX, the company behind IMU-935

See IMUX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMUX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.